Physician profile

Thomas Agesen

Physical Medicine & Rehabilitation · Parsippany, NJ

NPI 1497782940

$6,945.37

in general payments reported to CMS, 2019-2025

44 companies · $851 in 2025

The $851 reported for 2025 was more than what 86% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$2,694.39

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $1,194.69 2019-2025 Relistor
Collegium Pharmaceutical, INC. $746.96 2019-2025 Xtampza
Abbvie INC. $689.83 2021-2025 Ubrelvy, Qulipta, Botox
Scilex Pharmaceuticals INC. $450.23 2020-2025 Ztlido
Arbor Pharmaceuticals, INC. $442.71 2019-2022
Biodelivery Sciences International, INC. $354.32 2019-2021
Protega Pharmaceutials INC $287.84 2022-2025 Roxybond
Azurity Pharmaceuticals, INC. $259.37 2023-2025 Horizant, Horizant
Allergan, INC. $247.68 2019-2022
Ibsa Pharma INC. $202.48 2020-2023 Tirosint, Licart
Alphatec Spine, INC $185.96 2024 Invictus Mis
Pacira Therapeutics, INC. $178.40 2019-2021
Redhill Biopharma INC. $156.34 2020-2022
Daiichi Sankyo INC. $151.82 2019
Depuy Synthes Sales INC. $135.97 2019-2025 Orthovisc, Monovisc
Show all 44 companies
CompanyGeneral paymentsYearsTop products
Teva Pharmaceuticals USA, INC. $124.92 2019-2021
Pfizer INC. $124.32 2019-2023
Fidia Pharma USA INC. $109.61 2019-2023 Hymovis, Triluron
Lilly USA, LLC $93.25 2020-2022
Biohaven Pharmaceutical Holding Company LTD. $82.39 2022
Zimmer Biomet Holdings, INC. $79.83 2019-2023 Gel-One Cross-Linked Hyaluronate
Hikma Pharmaceuticals USA $70.69 2022
Ferring Pharmaceuticals INC. $50.31 2021-2024 Euflexxa
Orthogenrx INC. $49.59 2021
Virtus Pharmaceuticals LLC $48.81 2021-2025 Levorphanol Tartrate
Amgen INC. $44.84 2021-2022
Ossur Americas, INC. $37.51 2025 Unloader One X
Boston Scientific Corporation $37.20 2019-2024
Astrazeneca Pharmaceuticals LP $30.00 2019
Shionogi INC $27.49 2019
Vertical Pharmaceuticals, LLC $26.88 2019
Arteriocyte Medical Systems, INC. $26.53 2023 Magellan
Abbott Laboratories $25.95 2023 Proclaim
Bioventus LLC $20.79 2019
Takeda Pharmaceuticals U.S.A., INC. $20.74 2019
Vertex Pharmaceuticals Incorporated $16.21 2024
Nevro Corp. $15.31 2023 Senza
Biohaven Pharmaceuticals, INC. $15.00 2021
Merz Pharmaceuticals, LLC $14.92 2022
Electronic Waveform Lab, INC. $14.32 2023
Horizon Therapeutics Plc $13.58 2022
Kowa Pharmaceuticals America, INC. $13.33 2022
Heraeus Medical, LLC. $13.24 2021
Pacira Cryotech Incorporated $13.21 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Thomas Agesen

$6,945.37

in general payments reported 2019-2025

Years
2019-2025
Top company
Salix Pharmaceuticals, A Division of Bausch Health US, LLC
Context
The $851 reported for 2025 was more than what 86% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).

https://glasscript.com/doctor/157990/thomas-agesen

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.